CAYSTON POWDER FOR SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
15-05-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
AZTREONAM
Tillgänglig från:
GILEAD SCIENCES CANADA INC
ATC-kod:
J01DF01
INN (International namn):
AZTREONAM
Dos:
75MG
Läkemedelsform:
POWDER FOR SOLUTION
Sammansättning:
AZTREONAM 75MG
Administreringssätt:
INHALATION
Enheter i paketet:
2ML
Receptbelagda typ:
Prescription
Terapiområde:
MONOBACTAMS
Produktsammanfattning:
Active ingredient group (AIG) number: 0122819004; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2009-09-11
Produktens egenskaper
PRODUCT MONOGRAPH
PR
CAYSTON
®
AZTREONAM FOR INHALATION SOLUTION
75 MG AZTREONAM / VIAL
ANTIBIOTIC
_(ATC J01DF01) _
_ _
_ _
_ _
_ _
_ _
Gilead Sciences, Inc.
Foster City, CA 94404
USA
Gilead Sciences Canada, Inc.
Mississauga, ON
L5N 2W3
www.gilead.ca
Control No.: 234938_ _
Date of Revision:
May 15, 2020
CAYSTON
(aztreonam for inhalation solution)
Product Monograph
2
TABLE OF CONTENTS
PART I.
HEALTH PROFESSIONAL INFORMATION
................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
6
DRUG INTERACTIONS
..............................................................................................................................
9
DOSAGE AND ADMINISTRATION
........................................................................................................
10
OVERDOSAGE
..........................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
11
STORAGE AND STABILITY
....................................................................................................................
12
SPECIAL HANDLING
INSTRUCTIONS..................................................................................................
13
DOSAGE F
Läs hela dokumentet
